Galmed Pharma rises as FDA greenlights change in NASH trial

Eocene

02/08/2021 15:51

** Shares of Israel-based drug developer  GLMD.O  jump ~20%
to $3 
    ** Co says the FDA agreed with its plan to use a compound
called Aramchol meglumine, instead of a less water soluble form,
in its late-stage study for nonalcoholic steatohepatitis (NASH)
without conducting additional studies  urn:newsml:reuters.com:*:nPn81J07Da
    ** GLMD says the change can potentially improve convenience
and adherence to its once-daily treatment regimen of the
experimental drug
    ** NASH is the progressive form of non-alcoholic fatty liver
disease that can lead to cardiovascular disease, cirrhosis and
liver-related mortality
    ** Up to Friday's close, GLMD down ~20% YTD

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))